INSMED Inc (INSM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$1.3B, a net margin of -210.5%; the best year in this period was 2016 with -$176M.
Over the twelve months to September 30, 2026, revenue was $1.5B and net income -$606M.
Free cash flow was -$968M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 222% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5B | $606M | $364M | $305M | $245M | $188M | $164M | $136M | $10M | $0 | $0 |
| Gross profit | $1.3B | $483M | $278M | $240M | $190M | $144M | $125M | $112M | $7M | $0 | $0 |
| Operating income | -$564M | -$1.2B | -$878M | -$710M | -$457M | -$375M | -$265M | -$235M | -$307M | -$189M | -$173M |
| Net income | -$606M | -$1.3B | -$914M | -$750M | -$482M | -$435M | -$294M | -$254M | -$324M | -$193M | -$176M |
| EPS (diluted) | $-2.81 | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | $-4.22 | $-2.89 | $-2.85 |
| R&D | $944M | $771M | $598M | $571M | $398M | $273M | $181M | $132M | $145M | $110M | $123M |
| Revenue growth | — | +66.7% | +19.2% | +24.4% | +30.2% | +14.6% | +20.5% | +1287.6% | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$596M | -$935M | -$684M | -$536M | -$400M | -$363M | -$219M | -$251M | -$258M | -$160M | -$147M |
| Capital spending | -$32M | -$33M | -$22M | -$13M | -$10M | -$7M | -$6M | -$42M | -$13M | -$3M | -$4M |
| Free cash flow | -$628M | -$968M | -$706M | -$550M | -$410M | -$371M | -$226M | -$293M | -$271M | -$163M | -$151M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $167M | $153M | $97M | $75M | $58M | $46M | $36M | $27M | $26M | $18M | $18M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.4B | $1.4B | $780M | $1.1B | $717M | $533M | $487M | $495M | $381M | $163M |
| Debt | — | $568M | $1.1B | $1.2B | $1.2B | $831M | $483M | $490M | $450M | $56M | $55M |
| Equity | — | $739M | $285M | -$332M | $88M | $410M | $276M | $262M | $208M | $361M | $154M |
| Total assets | — | $2.3B | $2.0B | $1.3B | $1.7B | $1.2B | $796M | $742M | $605M | $462M | $238M |
| Shares (diluted) | 219M | 199M | 164M | 140M | 123M | 112M | 98M | 85M | 77M | 67M | 62M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 84.4% | 79.7% | 76.4% | 78.5% | 77.5% | 76.6% | 75.8% | 82.3% | 75.4% | — | — |
| Operating margin | -37.1% | -205.6% | -241.5% | -232.5% | -186.4% | -199.0% | -161.3% | -172.4% | -3124.9% | — | — |
| Net margin | -39.9% | -210.5% | -251.2% | -245.6% | -196.3% | -230.6% | -178.9% | -186.4% | -3297.2% | — | — |
| FCF margin | -41.3% | -159.5% | -194.1% | -180.1% | -167.2% | -196.6% | -137.2% | -214.6% | -2756.2% | — | — |
| ROIC | — | -75.3% | -48.7% | -64.8% | -28.6% | -30.1% | -27.6% | -24.7% | -36.9% | -45.3% | -65.4% |
| ROE | — | -172.8% | -320.2% | 225.8% | -547.5% | -105.9% | -106.6% | -97.2% | -155.7% | -53.4% | -114.1% |
Frequently asked questions
What is INSMED’s annual revenue?
$606M in fiscal 2025 and $1.5B over the twelve months to September 30, 2026.
How much profit does INSMED make?
Net income was -$1.3B in fiscal 2025 (net margin -210.5%).
Is INSMED’s revenue growing?
Yes: revenue rose 66.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.